Estrella Immunopharma (NASDAQ:ESLA) Stock Rating Lowered by Wall Street Zen

Estrella Immunopharma (NASDAQ:ESLA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

ESLA has been the topic of several other research reports. D. Boral Capital restated a “buy” rating and issued a $16.00 price objective on shares of Estrella Immunopharma in a research report on Monday, November 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Estrella Immunopharma in a report on Friday, October 31st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $16.00.

Estrella Immunopharma Stock Performance

NASDAQ:ESLA opened at $0.99 on Friday. Estrella Immunopharma has a one year low of $0.73 and a one year high of $3.15. The firm has a market cap of $37.54 million, a price-to-earnings ratio of -2.92 and a beta of 0.55. The firm’s fifty day moving average is $1.68 and its two-hundred day moving average is $1.41.

Estrella Immunopharma (NASDAQ:ESLA) last issued its earnings results on Wednesday, November 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.